CRISPR Therapeutics AG (NASDAQ:CRSP) Holdings Boosted by Westside Investment Management Inc.

Westside Investment Management Inc. boosted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.7% during the 1st quarter, HoldingsChannel reports. The firm owned 7,393 shares of the company’s stock after buying an additional 332 shares during the quarter. Westside Investment Management Inc.’s holdings in CRISPR Therapeutics were worth $504,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CRSP. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after purchasing an additional 1,372,986 shares in the last quarter. Norges Bank acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $38,661,000. Vestmark Advisory Solutions Inc. acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $10,848,000. PBCay One RSC Ltd acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $10,329,000. Finally, Trexquant Investment LP acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $8,287,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Barclays decreased their target price on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a research note on Thursday, May 9th. Piper Sandler reissued an “overweight” rating and set a $105.00 target price on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Mizuho lifted their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Guggenheim reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Finally, Robert W. Baird lifted their price objective on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $75.71.

Insider Transactions at CRISPR Therapeutics

In other news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares in the company, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $53.90 on Thursday. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The firm has a fifty day moving average price of $56.59 and a two-hundred day moving average price of $64.33.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. During the same quarter last year, the firm posted ($0.67) EPS. The business’s revenue for the quarter was down 99.5% on a year-over-year basis. Analysts forecast that CRISPR Therapeutics AG will post -5.51 EPS for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.